Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055783 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00055783: Completed Phase 2 study, sponsored by Stanford University.
NCT00055783 is a Phase 2 study that has completed, run by Stanford University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055783, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have progressive or recurrent Hodgkin's lymphoma.
Interventions
- BIOLOGICAL apolizumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-07 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
What the finished NCT00055783 record still lists
NCT00055783 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which apolizumab is the first listed.
NCT00055783 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055783 about?
NCT00055783 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have progressive or recurrent Hodgkin's...
What is the current status of trial NCT00055783?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-07. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00055783?
The interventions under investigation include: apolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055783?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia